Kevin Bersell

Kevin a post-doctoral fellow under the mentorship of Drs. Christine and Jonathan Seidman at Harvard Medical School. He completed his MD and PhD training at Vanderbilt University in Nashville, TN under the mentorship of Dr. Dan Roden. In his graduate work, he studied the transcriptional and functional mechanisms of rare variants associated with inherited arrhythmia syndromes using human stem cell derived cardiomyocytes and mouse models of disease. His current work advances the CureHeart mission to develop gene therapy strategies to address dominant negative genetic mechanisms of disease. 

Publications:    

1. Transcriptional dysregulation in patient-specific stem cells underlies both monogenic arrhythmia syndromes and common arrhythmia risk. Bersell KR et al. (2023). Circulation
2. A partial duplication and poly(A) insertion in KCNQ1 not detected by next-generation sequencing in Jervell and Lange-Nielsen Syndrome. Bersell K et al. (2016) Circulation: Arrhythmia and Electrophysiology
3. Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of the Heart Injury. Bersell K et al. (2009). Cell
4. Cardiomyocyte proliferation contributes to heart growth in young humans. Mollova M and Bersell K et al. (2013). Proceedings of the National Academy of Sciences USA
5. Moderate and high amounts of tamoxifen in α-MHC-MerCreMer mice induce a DNA damage response, leading to heart failure and death. Bersell K and Choudhury S et al. (2013). Disease Models and Mechanisms